News & Events CTI Announces Singapore Location

CTI Announces Singapore Location

January 29, 2018

CTI Clinical Trial & Consulting Services Announces Continued Growth in Asia

Picture of the exterior of the new CTI Office in SingaporeFOR IMMEDIATE RELEASE [Covington, KY ~ 29, January 2018] CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization announces that it has opened offices in Singapore. The offices are opened through the wholly-owned subsidiary, CTI Clinical Trial and Consulting Services Singapore Pte. Ltd. The company has opened more than a dozen offices over the past few years, with additional international expansion planned in Asia over the next 12-18 months. The company established their Pacific-Asia headquarters in Sydney, Australia several years ago.

“The expansions in Singapore is part of continued efforts to increase our clinical research offerings across Asia,” explains Patrick Earley, Vice President, International. “We have been working across Asia for a number of years, and have decided that establishing a more permanent presence in Singapore and other countries in Asia would allow us to  further enhance relationships with local medical centers and biotechnology companies."

The company announced the opening of offices in Taipei, Taiwan and Tokyo, Japan in June of 2017.

CTI has been working for nearly two decades in the drug development industry across North America, Europe, South America, Pac-Asia, and Africa, specializing in clinical research programs involving critically ill patient populations, and has more than 25 offices worldwide to serve more than 120 pharmaceutical, biotechnology, and medical device clients.

About CTI Clinical Trial and Consulting Services

CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in the Greater Cincinnati, OH area, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit

Subscribe to our mailing list

* indicates required